Recro Pharma Inc. (NASDAQ:REPH)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Tuesday. They presently have a $19.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 137.50% from the stock’s current price.

Several other research firms have also recently weighed in on REPH. Roth Capital set a $24.00 price target on shares of Recro Pharma and gave the company a “buy” rating in a report on Monday. Brean Capital reiterated a “buy” rating and issued a $28.00 price target on shares of Recro Pharma in a report on Thursday, August 11th. Zacks Investment Research upgraded shares of Recro Pharma from a “sell” rating to a “hold” rating in a report on Friday, August 26th. Janney Montgomery Scott assumed coverage on shares of Recro Pharma in a report on Monday, August 29th. They issued a “buy” rating and a $21.00 price target for the company. Finally, Aegis assumed coverage on shares of Recro Pharma in a report on Monday, November 14th. They issued a “buy” rating and a $21.00 price target for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $19.13.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Recro Pharma (NASDAQ:REPH) opened at 8.00 on Tuesday. Recro Pharma has a 1-year low of $5.59 and a 1-year high of $12.50. The firm’s market capitalization is $97.30 million. The company has a 50-day moving average of $7.71 and a 200-day moving average of $8.33.

ILLEGAL ACTIVITY WARNING: “Recro Pharma Inc. (REPH) Rating Reiterated by HC Wainwright” was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this news story on another domain, it was stolen and republished in violation of US & international copyright and trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2016/12/01/recro-pharma-inc-reph-rating-reiterated-by-hc-wainwright.html.

Several hedge funds have recently made changes to their positions in the company. Stonepine Capital Management LLC raised its stake in shares of Recro Pharma by 81.0% in the second quarter. Stonepine Capital Management LLC now owns 428,670 shares of the specialty pharmaceutical company’s stock worth $3,408,000 after buying an additional 191,796 shares in the last quarter. Granite Point Capital Management L.P. purchased a new stake in Recro Pharma during the third quarter valued at about $636,000. Acadian Asset Management LLC purchased a new stake in Recro Pharma during the third quarter valued at about $140,000. Northern Trust Corp purchased a new stake in Recro Pharma during the third quarter valued at about $128,000. Finally, BlackRock Institutional Trust Company N.A. raised its stake in Recro Pharma by 30.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 49,947 shares of the specialty pharmaceutical company’s stock valued at $397,000 after buying an additional 11,682 shares during the period. 52.28% of the stock is currently owned by institutional investors and hedge funds.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

5 Day Chart for NASDAQ:REPH

Receive News & Stock Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related stocks with our FREE daily email newsletter.